As NKG2D, DNAM-1 has been shown to be involved in immune responses against different tumors like prostate cancer, ovarian neoplasia and multiple myeloma (da Silva et al., 2014; Fionda et al., 2015; Pasero et al., 2015). This evidence concerns the gene CD226 and AL amyloidosis.